All uses except for Canadian college and university publishing - Immunotherapy, cancer treatment. The principle of immunotherapy consists of injecting anti-PD-L1 (or anti-PD-1) immunomodulators into the patient. PD-L1 receptors on the tumor cell (in red) are shown in yellow. While lymphocyte PD-1 receptors (in blue) are shown in light blue. The anti PD-L1 (dark green) and anti PD-1 (light green) immunomodulators bind to the corresponding receptors. Thus they block the connection between these two receptors (yellow and blue). Therefore they block the brake of the immune reaction caused by the PD-L1 PD-1 binding. So the interaction between PD-L1 and PD-1 is prevented. Thus, the T lymphocyte again destroys the cancer cells it recognizes. - Restriction : Canada College and University Publishing Exclusion from 05/03/2021